| (i) | Information about reportable segment |
The Company is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The activities are either conducted as own project development or for third party companies. Management of resources and reporting to the chief operating decision maker is based on the Company as a whole.
| (ii) | Geographic information |
The geographic information below analyzes the Company’s revenue and non-current assets by country. In presenting the following information, segment revenue has been based on the geographic location of the customers and segment assets were based on the geographic location of the assets.
Discovery activities and research services are conducted in both the Heidelberg and Plzen premises. Pre-clinical and clinical activities are conducted and coordinated from Heidelberg.
| 2015 | 2016 | 2017 | ||||||||||
| Revenues: | ||||||||||||
| Germany | 125 | 6 | 80 | |||||||||
| Europe | 711 | 1,397 | 1,236 | |||||||||
| USA | 6,725 | 4,911 | 694 | |||||||||
| 7,562 | 6,314 | 2,010 | ||||||||||
| Non-current assets as of December 31: | ||||||||||||
| Germany | 618 | 957 | ||||||||||
| Czech Republic | 259 | 221 | ||||||||||
| 877 | 1,178 | |||||||||||
| (iii) | Major Customers |
For the years ended December 31, 2015, 2016 and 2017, the Company’s revenue with two, three and four customers, respectively, exceeded 10% of total revenues.